Ikena Oncology Announces $40 Million Underwritten Offering
15 Mayo 2023 - 6:45AM
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a
targeted oncology company forging new territory in patient-directed
cancer treatment, announced today the pricing of an underwritten
offering of 6,110,000 shares of common stock (the “Shares”) at an
offering price of $6.55 per share. The gross proceeds to the
Company, before deducting the underwriting discounts and
commissions and estimated offering expenses, are expected to be
approximately $40 million. The offering is expected to close on or
about May 17, 2023, subject to satisfaction of customary closing
conditions. The Company anticipates the net proceeds of the
offering, together with existing cash, cash equivalents and
investments, to further its ongoing clinical development of
targeted oncology programs and advance them to clinical data read
outs beyond the initial data for the monotherapy portion of the
ongoing IK-930 Phase 1 clinical trial in the fourth quarter of 2023
and initial clinical data for IK-595, in addition to working
capital, capital expenditures and other general corporate purposes.
The financing was co-led by a new healthcare dedicated investor and
included additional new investors, Acuta Capital Partners, Adage
Capital, and Vestal Point Capital, as well as participation from
existing investors.
TD Cowen and William Blair are acting as joint book-runners for
the offering and H.C. Wainwright & Co. is acting as lead
manager for the offering.
A shelf registration statement on Form S-3 (File No. 333-264517)
relating to the offering of the securities described above was
filed with the Securities and Exchange Commission (“SEC”) on April
27, 2022 and became effective on May 5, 2022. The offering is being
made only by means of a prospectus, including a prospectus
supplement, forming a part of an effective registration statement.
A prospectus supplement and accompanying prospectus relating to the
shares of common stock being offered was filed with the SEC on May
15, 2023. Copies of the prospectus supplement and accompanying
prospectus relating to the offering may be obtained on the SEC’s
website at http://www.sec.gov or from Cowen and Company, LLC, Attn:
Cowen and Company, LLC, , 599 Lexington Avenue, New York, NY 10022,
by email at Prospectus_ECM@cowen.com or by telephone at (833)
297-2926. These copies may also be obtained by contacting William
Blair & Company, L.L.C. at 150 North Riverside Plaza, Chicago,
Illinois 60606, Attention: Prospectus Department, by telephone at
(800) 621-0687, or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Ikena Oncology
Ikena Oncology™ is focused on developing differentiated
therapies for patients in need that target nodes of cancer growth,
spread, and therapeutic resistance in the Hippo and RAS
onco-signaling network. The Company’s lead targeted oncology
program, IK-930, is a TEAD1 selective Hippo pathway inhibitor, a
known tumor suppressor pathway that also drives resistance to
multiple targeted therapies. The Company’s additional research
spans other targets in the Hippo pathway as well as the RAS
signaling pathway, including developing IK-595, a novel MEK-RAF
inhibitor. Additionally, IK-175, an AHR antagonist, is being
developed in collaboration with Bristol Myers Squibb. Ikena aims to
utilize their depth of institutional knowledge and breadth of tools
to efficiently develop the right drug using the right modality for
the right patient. To learn more, visit www.ikenaoncology.com or
follow us on Twitter and LinkedIn.
Forward Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, that involve risks and uncertainty. Such
statements are based on management’s current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that
there can be no assurance that actual results will not differ
materially from those projected or suggested in such
forward-looking statements as a result of various factors. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Forward-looking statements include, but are not
limited to, the Company’s expectations regarding the completion of
the offering. Important factors that could cause actual results to
differ significantly from those expressed or implied by such
forward-looking statements include, but are not limited to: risks
and uncertainties related to market and other conditions and the
satisfaction of customary closing conditions related to the
offering. A further list and description of these and other
factors, risks and uncertainties can be found in the “Risk Factors”
section of the Company’s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2023, which is on file, which we filed with
the Securities and Exchange Commission on May 15, 2023, the
prospectus supplement related to this offering and subsequent
filings. Forward-looking statements represent the Company’s views
only as of today and should not be relied upon as representing its
views as of any subsequent date. The Company explicitly disclaim
any obligation to update any forward-looking statements.
Investor Contact:Rebecca CohenIkena
Oncologyrcohen@ikenaoncology.com
Media Contact:Luke ShiploLifeSci
Communicationslshiplo@lifescicomms.com
Ikena Oncology (NASDAQ:IKNA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Ikena Oncology (NASDAQ:IKNA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024